Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 7/17/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Stuart Aaronson?

Stuart A. Aaronson

Chair, Department of Oncological Sciences

Mount Sinai School of Medicine

HQ Phone:  (212) 241-6500

Direct Phone: (212) ***-****direct phone

Email: s***@***.edu

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Mount Sinai School of Medicine

Box 1497 , One Gustave L. Levy Place

New York City, New York,10029

United States

Company Description

Located in Manhattan, Mount Sinai School of Medicine is internationally recognized for ground-breaking clinical and basic-science research, and innovative approaches to medical education. Through the Mount Sinai Graduate School of Biological Sciences, Mount Si...more

Web References(82 Total References)


NYSSMOH - New York State Society of Medical Oncologists & Hematologists

www.nyssmoh.org [cached]

At the recent annual meeting, held September 10, 2012 at the New York Academy of Medicine, Dr Stuart Aaronson of the Mount Sinai School of Medicine, spoke on the topic of "Translating Cancer Gene Discoveries to the Clinic".


www.bcrfcure.org

Stuart A. Aaronson, MD
Dr. Aaronson continues his work on identifying breast cancer biomarkers and his research using a Wnt autocrine transforming mechanism in triple negative breast tumors to develop novel therapies for these tumors. His team recently established a human inflammatory breast cancer line, whose characterization could provide insights into specific therapies for this aggressive breast malignancy. They also identified aberrant epigenetic regulation of erbB2 in HER2-positive (HER2+) subtype breast tumors. These findings provide better understanding of how this gene becomes overexpressed in breast cancers and identify possible new therapeutic targets in erbB2 positive breast cancers. Bio: At the National Cancer Institute as Chief, Laboratory of Cellular and Molecular Biology, Dr. Stuart Aaronson's early investigations of mammalian transforming retroviruses led to the discovery of the first normal function of an oncogene and demonstration that genes encoding growth factors could be transforming (sis/PDGF). He and his colleagues subsequently discovered ErbB2 as an erbB related gene amplified in a primary human breast cancer, and genes for other growth factor signaling molecules, that could also be activated as oncogenes in human malignancies. Dr. Aaronson's research has contributed to novel cancer drugs including Herceptin, which targets ERBB2, and KGF/FGF7, discovered by this team as a unique epithelial cell acting growth factor, which became Kepivance, for treatment of cancer therapy associated mucositis. Other discoveries, including erbB3, PDGFR alpha, and HGF as the ligand for MET, have also led to agents currently in clinical development as cancer therapeutics. Dr. Aaronson joined Mount Sinai in 1993 and initiated studies of Wnt signaling with the goal of identifying novel Wnt activation mechanisms such as Wnt autocrine signaling in human tumors. His team identified and cloned cell surface acting Wnt antagonists, FRP and DKK1, established their mechanisms of action, and contributed to understanding of Wnt co-receptor activation. Using these and other approaches, they have established that autocrine Wnt signaling is a common mechanism of Wnt canonical pathway activation in human tumors ranging from epithelial malignancies including breast, ovarian, and non-small cell lung carcinomas, to a wide array of mesenchymally derived sarcomas. Dr. Aaronson has also identified novel p53 functions in cell stress responses and transcriptional mechanisms differentially regulating p53 growth arrest and apoptosis. He has published extensively on growth control and cancer, holds more than 50 patents, and has trained dozens of investigators, who are in academic positions, biotech/pharma, or head cancer centers/institutes in the US and abroad.


Curis - Controling regeneration signaling pathways to restore human health

www.curis.com [cached]

Stuart A. Aaronson, M.D.
Dr. Aaronson is currently the Chairman for the Department of Oncological Sciences at The Mount Sinai Medical Center in New York City, and the Jane B. and Jack R. Aron Professor of Neoplastic Diseases at the school. Dr. Aaronson is the author of more than 530 publications, an inventor on more than 50 patents and serves on numerous editorial boards and scientific advisory committees.


Mount Sinai - Shared Research Facilities

webp3-prod.mountsinai.org [cached]

Stuart Aaronson, M.D.
Stuart Aaronson, M.D.


webp5-prod.mountsinai.org

Stuart Aaronson, M.D.Professor and Chair of Oncological Sciences


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory